Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02083289 · ClinicalTrials.gov registry record · Phase 2
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A Phase 2 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Ono Pharmaceutical Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
- 12
- Study locations
NCT02083289 is a Phase 2 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Ono Pharmaceutical Co.. The registered enrollment target is 123 participants, below the 276-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (55% lower). The trial reports 12 study locations across 6 states.
The verdict
NCT02083289, a Phase 2 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Ono Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.
Conditions Studied
Interventions
- DRUG Latanoprost
- DRUG ONO-9054
Study Locations (12)
California
- Los Angeles Clinical Site - Los Angeles
- Mission Hills Clinical Site - Mission Hills
- Newport Beach Clinical Site - Newport Beach
- Pasadena Clinical Site - Pasadena
- Petaluma Clinical Site - Petaluma
Georgia
- Morrow Clinical Site - Morrow
- Roswell Clinical Site - Roswell
Pennsylvania
- Cranberry Township Clinical Site - Cranberry Township
- Philadelphia Clinical Site - Philadelphia
New York
- New York Clinical Site - New York
North Carolina
- High Point Clinical Site - High Point
Texas
- Austin Clinical Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02083289
The ClinicalTrials.gov registry entry for NCT02083289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 276-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (55% lower). The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Latanoprost is the first listed.
NCT02083289 reports 12 study locations spanning 6 distinct geographic areas - top geographies include California, Georgia, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02083289 about?
NCT02083289 is a clinical study titled "A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)". The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.
What is the current status of trial NCT02083289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2014-05.
What conditions does trial NCT02083289 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT02083289?
The interventions under investigation include: Latanoprost (DRUG), ONO-9054 (DRUG).
Who is sponsoring clinical trial NCT02083289?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02083289 being conducted?
This trial has 12 study locations across California, Georgia, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.